A notable advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, https://fellowfavorite.com/story22661136/revolutionary-development-tirzepatide-strength-for-diabetes-management